Drug Discovery World

OCTOBER 11, 2023

Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA).

Clinical Trials 130

Clinical Trials Treatment Trials FDA Approval 130

Drug Discovery World

DECEMBER 7, 2023

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. The post Potentially game-changing schizophrenia drug enters Phase I trials appeared first on Drug Discovery World (DDW).

Trials 299

Trials Drugs Clinical Trials Licensing 299

Drug Discovery World

AUGUST 28, 2024

It is approved for the first-line treatment of adult patients with unresectable or metastatic cancer, who are eligible for platinum-containing chemotherapy. I look forward to seeing the treatment combination implemented as a first-line regimen in the clinical setting.” months compared to 16.1 The median PFS of 12.5

Treatment 130

Treatment Clinical Trials Trials FDA 130

Drug Discovery World

JUNE 6, 2024

Lorbrena advances lung cancer treatment New data show that an unprecedented 60% of patients with advanced lung cancer given Lorbrena (lorlatinib) remain alive without disease progression after five years.

Drug Research 195

Drug Research Research Vaccine Clinical Trials 195

Drug Discovery World

JUNE 6, 2023

Researchers from the University of Manchester and Link Biologics have revealed preclinical data on a potential new treatment for osteoarthritis. The data is promising and whilst the research is in its early stages, it shows that Link_TSG6 has the potential to offer a new class of disease modifying drugs to treat osteoarthritis.”

Treatment 130

Treatment Research Clinical Trials Disease 130

Drug Discovery World

JULY 5, 2024

The Division of Clinical Neuroscience at Oslo University Hospital (OUS) and the Swedish drug development company TikoMed have signed a research collaboration agreement focused on amyotrophic lateral sclerosis (ALS).

Drug Research 204

Drug Research Research Hospitals Drugs 204

Drug Discovery World

SEPTEMBER 6, 2024

The Phase II NANOBRAINMETS trial of AGuIX has been validated by the Data Safety and Monitoring Board (DSMB) following a futility analysis scheduled after the enrolment and follow-up of 50% of patients in the study. A total of 96 patients have been randomised to date of the 134 scheduled in the study’s protocol.

Trials 130

Trials Clinical Trials Clinical Development Hospitals 130

Drug Discovery World

APRIL 30, 2024

Four new LifeArc Translational Centres for Rare Diseases have been created to give people living with rare medical conditions access to improved tests and treatments. They aim to tackle barriers that ordinarily prevent new tests and treatments reaching patients with rare diseases and speed up the delivery of rare disease treatment trials.

Research 130

Research Disease Trials Treatment 130

Drug Discovery World

AUGUST 19, 2024

CV6 Therapeutics has initiated patient dosing in Phase Ia clinical trial evaluating its investigational first-in-class, specific dUTPase inhibitor CV6-168 + infusional 5-fluorouracil (5-FU).

Trials 147

Trials Therapies DNA Small Molecule 147

Drug Discovery World

JUNE 24, 2024

Scientists at the Brain Tumour Research Centre of Excellence at the University of Plymouth are conducting a clinical trial to see whether using anti-retroviral medications, ritonavir and lopinavir, could help people with Neurofibromatosis 2 (NF2).

Clinical Trials 147

Clinical Trials Trials Drugs DNA 147

Drug Discovery World

JULY 5, 2024

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD).

Treatment 147

Treatment Medical Schools Trials Clinical Trials 147

Drug Discovery World

JUNE 25, 2024

A new study demonstrates that AI-powered digital twin solutions can potentially replace the standard-of-care (SOC) control arm of a clinical trial. Phesi created a digital twin for chronic graft versus host disease (cGvHD) in the primary treatment setting.

Clinical Trials 147

Clinical Trials Trials Hospitals Clinical Research 147

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 147

Trials Clinical Trials Treatment Research 147

Drug Discovery World

MAY 8, 2024

Calliditas Therapeutics has announced data from the proof-of-concept Phase II trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN).

Trials 173

Trials Clinical Trials Treatment Disease 173

Drug Discovery World

JULY 12, 2024

Scientists at the University of Oxford in the UK have launched a new clinical trial to test a vaccine to protect against “devastating” Marburg virus. This is the first-in-human trial of the ChAdOx1 Marburg vaccine, which has been developed and manufactured by researchers at the University of Oxford.

Virus 147

Virus Vaccine Trials Clinical Trials 147

Drug Discovery World

NOVEMBER 8, 2023

Deepika Khedekar , Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. Tapping into the capabilities of AI One reason AI may accelerate clinical trials is its ability to rapidly process and analyse vast amounts of data.

Clinical Trials 182

Clinical Trials Trials Disease Medical Schools 182

Drug Discovery World

AUGUST 24, 2022

A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments. . The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment.

Research 246

Research Clinical Trials Virus Trials 246

Drug Discovery World

DECEMBER 16, 2022

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia. . Along with positive Phase II trial data for talquetamab , the company presented promising findings on the long-term results of daratumumab in newly diagnosed, transplant-ineligible multiple myeloma patients. .

Trials 130

Trials Treatment Clinical Trials Therapies 130

Drug Discovery World

JANUARY 18, 2024

The results, together with the data from the recent LPS human challenge trial, further support the strategic expansion of the Phase II ready POLB 001 to treat and prevent cancer immunotherapy-induced CRS. Reductions were seen in all serum proinflammatory cytokines tested.

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

AUGUST 9, 2024

The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. The dose expansion portion of the study will evaluate treatment at the recommended Phase II dose in multiple indications.

Trials 147

Trials Pharmacokinetics Drugs Clinical Trials 147

Drug Discovery World

SEPTEMBER 15, 2022

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone.

Trials 130

Trials Treatment Clinical Trials Hospitals 130

Drug Discovery World

AUGUST 27, 2024

Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. Assessing psychiatric effects of CB1 inhibition The clinical trial will enrol 120 patients across four treatment groups.

Trials 130

Trials Small Molecule Clinical Trials Treatment 130

Drug Discovery World

JANUARY 11, 2024

Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. ” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW).

Drug Trials 246

Drug Trials Trials Small Molecule Clinical Trials 246

Drug Discovery World

MAY 14, 2024

In the clinic, I am always involved in clinical trials, both industry-initiated and investigator-initiated. The neoadjuvant concept has become an ideal platform for both drug discovery and translational research. MT: What industry-wide drug discovery breakthrough has most impacted your research?

Research 147

Research Hospitals Trials Clinical Trials 147

Drug Discovery World

JULY 5, 2024

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. Targeted, minimally-invasive delivery AVB-101 is delivered as a one-time-only treatment using a minimally invasive, stereotactic neurosurgical procedure directly to the thalamus.

Therapies 147

Therapies Trials Clinical Trials Clinical Development 147

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. In the UK, according to Cancer Research UK, around 167,000 people die from cancer in the UK each year. Research into new drugs and therapeutics is on-going and is helping drive mortality rates down.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

JULY 30, 2024

A new partnership between NHS Scotland, AstraZeneca and the Universities of Dundee and Glasgow hopes to accelerate research into treating chronic kidney disease. As we navigate the complex issue of chronic kidney disease, our commitment to patient-centred research remains unwavering.

Disease 130

Disease Research Government Clinical Trials 130

Drug Discovery World

JUNE 21, 2024

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse.

Trials 147

Trials Compliance Clinical Trials Doctors 147

Drug Discovery World

JUNE 19, 2024

New research has uncovered how different people respond to sepsis based on their genetics, which could lead to the development of targeted therapies. The ultimate aim is for patients to receive the most effective treatment for their sepsis more quickly, based on their immune response rather than their symptoms.

Immune Response 162

Immune Response Treatment Regulations Therapies 162

Drug Discovery World

JUNE 3, 2024

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments.

Vaccine 147

Vaccine Trials Clinical Trials Hospitals 147

Drug Discovery World

MARCH 10, 2023

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. If successful in clinical trials the investigational candidates may have the potential to offer cancer patients access to new targeted treatment options.

Research 246

Research Clinical Trials Clinical Development Trials 246

ProRelix Research

SEPTEMBER 7, 2023

Autoimmune disorders comprise several diseases in which the immune system mistakenly attacks and destroys the body’s own healthy cells instead of destroying bacteria and viruses to keep the body healthy. […] The post Autoimmune disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.

Clinical Trials 105

Clinical Trials Trials Treatment Virus 105

ProRelix Research

MAY 31, 2023

Introduction: Clinical trials are a crucial component of the pharmaceutical and medical research industry, aimed at evaluating the safety and effectiveness of new drugs, treatments, or medical devices before they […] The post Successful Clinical Trial With ProRelix Research: Phase 1, 2, 3 & 4 Clinical Trial Services at … appeared (..)

Clinical Trials 98

Clinical Trials Trials Research Pharmaceuticals 98

ProRelix Research

SEPTEMBER 17, 2023

Since […] The post Ophthalmology disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.

Clinical Trials 98

Clinical Trials Trials Treatment Disease 98

Drug Discovery World

JUNE 5, 2024

The new partnership, which will involve scientists from both organisations working closely together, is part of LifeArc’s MND Translational Challenge, aimed at discovering innovative and potentially disease-modifying treatments for MND, a key component of the new UK MND Research Institute.

Bioinformatics 173

Bioinformatics Research Drugs Clinical Trials 173

Drug Discovery World

APRIL 8, 2024

Scientists from Gwangju Institute of Science and Technology in Korea have discovered compound 11c, a potentially ground-breaking oral treatment for metabolic dysfunction-associated steatohepatitis. Their research signals a transformative leap in liver disease management, addressing both inflammation and fibrosis.

Disease 130

Disease Treatment Pharmacokinetics Clinical Trials 130

Drug Discovery World

OCTOBER 18, 2023

Prostate cancer’s resistance to treatment can be reversed in some patients by stopping hijacked white blood cells from being ‘pulled into’ tumours, according to new research published in Nature. “The impact of this research could be very broad, across multiple cancer types.”

Research 162

Research Drugs Clinical Trials Treatment 162